Enterocytozoon bieneusi in AIDS: symptomatic relief and parasite changes after furazolidone

D Dionisio, L Ibba Manneschi, S Di Lollo, A Orsi, G S Terrantino, M Meli, M Gabbirelli, A Tani, A Papucci, F Leoncini

Abstract

**Aims**—To investigate changes in morphology of the developmental stages of *Enterocytozoon bieneusi* and symptomatic relief observed in AIDS patients after treatment with furazolidone.

**Methods**—Six AIDS patients with symptomatic *E. bieneusi* infection of the small intestine were treated with a course of furazolidone. All patients had a weekly monitoring of parasite shedding in stool by light microscopy during and after treatment. At the end of the treatment, duodenal biopsy specimens obtained from three patients were studied by transmission electron microscopy by two pathologists who were unaware of the patients' treatment.

**Results**—All patients showed both clinical and parasitological response with transient clearance or decrease of spore shedding in stool. After treatment, alterations in faecal spores were observed in all patients by light microscopy, and ultrastructural changes in *E. bieneusi* at all stages of the life cycle were demonstrated in biopsy specimens of the three patients who underwent post-treatment endoscopy.

**Conclusions**—The clinical benefit seen after treatment with furazolidone in six AIDS patients with *E. bieneusi* intestinal infection may be due to damage to the developmental stages causing a partial inhibition to reproduction of the parasite.

*Enterocytozoon bieneusi* is a microsporidian that causes chronic diarrhoea in severely immunocompromised patients with AIDS. Currently no established therapy is available because none of the available agents lead to eradication of the infection nor significantly affect the life cycle of the parasite; moreover, relapses rapidly occur after treatment is discontinued.

Furazolidone is a synthetic nitrofuran that is active against a broad spectrum of Gram negative and Gram positive bacteria as well as against some intracellular or extracellular...
Symptomatic relief and changes in E. bieneusi after furazolidone

protozoa (trichomonas, giardia, entamoeba, blastocystis, leishmania). One report about its effectiveness against Isospora belli has also been published. Activity of furazolidone results from its ability to inhibit various enzymes of the Krebs cycle, namely those involved in the acetyl-CoA synthesis from piruvate. Following oral administration the drug is well absorbed and achieves therapeutic concentrations in blood and significant concentrations in bile and urine. It has a good safety profile and does not alter the normal intestinal flora. In a preliminary study in three AIDS patients the drug induced remission of E. bieneusi infection symptoms as well as transient stopping of spore shedding in stool.

This study aimed to confirm the clinical benefit of furazolidone and to describe alterations of parasite morphology in stool and in duodenal biopsy specimens after treatment.

Methods

Six HIV infected men with symptomatic E. bieneusi infection were studied, including the three patients from the preliminary work. The patients' ages ranged between 26 and 36 years (mean 30.6). Three patients were drug addicts, two were homosexuals, and one was haemophiliac. CD4⁺ T cell counts ranged between 8 and 46 × 10⁹/l (mean 24). All six patients had AIDS at the time of study entry; AIDS defining events were oesophageal candidiasis in three cases, cryptococcosis in two cases, and Kaposi's sarcoma in one case. All patients had chronic diarrhoea (at least two months) with one to six watery stools per day. Weight loss ranged between 3 and 10 kg (mean 5.5).

Stool were processed according to the method of Weber et al and Van Gool et al to detect microsporidia. The amount of spore shedding was evaluated by a semiquantitative criterion on 100 microscopic fields: spores were defined as very frequent if present in every field, frequent if present in more than 50 but fewer than 100 fields, rare if present in fewer than 50 fields, and very rare if sporadically present. Before study entry, frequent to very frequent spores of microsporidia were present in stool of all patients. Stool samples were also examined for bacteria, Clostridium difficile toxin, mycobacteria, eggs and parasites, adenoviruses, and rotavirus; with negative results.

Transmission electron microscopy (TEM) was performed on endoscopic biopsy specimens taken from the third tract of duodenum, before treatment. At least two samples from each patient were processed. Specimens were fixed with glutaraldehyde 2.5% in cacodylate buffer (pH 7.4) for three to four hours at room temperature, washed in the same buffer and postfixed in osmium tetroxide in 1% Milloning buffer (Sic, Rome, Italy) for one hour at room temperature. After dehydration through graded acetone series, the specimens passed through propylene oxide and were embedded in Epon 812. Semi-thin sections (2 µm) were cut, stained with toluidine blue-Na tetraborate and studied under light microscope. About 100 ultrathin sections were obtained from all the selected specimens and were stained with uranyl acetate and alkaline bismuth subnitrate. For each section at least three random fields were examined by TEM. Care was taken to evaluate only areas away from the borders of the biopsy specimen to avoid traumatic artefact.

The haemophiliac patient denied consent for endoscopic biopsies, and TEM study of biopsy specimens was negative in one of the homosexual patients. In these two patients the diagnosis of E. bieneusi infection was achieved by a TEM study of stool samples collected before treatment. Stool specimens were fixed in 10% formalin, and excess faecal debris was removed.
Furazolidone—N-(5-nitro-2-furfurilidene)-3 amino-2-oxazolidone—100 mg tablets, was given orally four times daily for 20 days to one group of three patients (cases 1–3). The remaining three patients (cases 4–6) were treated with furazolidone 100 mg tablets five times daily for 18 days. Written informed consent was obtained before treatment. No concomitant antidiarrhoeal drugs were administered. Clinical assessment, and haematological and liver function tests were monitored after 10 days and at the end of the treatment. Adverse events to the drug were evaluated.

In all patients spore shedding in stool was monitored weekly during and after treatment with both Weber’s and Van Gool’s stains, and stool frequency and body weight were recorded.

The three patients treated with furazolidone for 18 days underwent upper intestinal endoscopy three days after completion of therapy. At least two biopsy specimens were taken from the third part of duodenum and processed as described above. Ultrathin sections were examined by TEM by two pathologists blind to the patients’ treatment or clinical outcome. In the same patients a TEM study on stool samples collected during the follow up period was also done as described above.

Results

CLINICAL RESPONSE

In all patients there was remission of diarrhoea within two weeks of starting treatment, and clearance or great decrease of spore shedding in stool after treatment were observed. Neither side effects nor alterations in the laboratory parameters attributable to the drug were observed.

Case 1 showed persistent clinical remission over the two months following completion of treatment and body weight increase. Subsequently, relapse of diarrhoea with very frequent faecal spores required a new cycle with furazolidone 200 mg three times daily for three days. Diarrhoea resolved within one day and re-examination of stool one week later demonstrated only very rare spores. Normal bowel movements with formed stool lasted until the patient died, 40 days later, having developed systemic cytomegalovirus.

Case 2 had intermittent shedding of very rare spores in stool, but he had neither clinical nor parasitological evidence of reactivation until he died one month later from unexplained acute abdomen.

Case 3 remained asymptomatic with only very rare spores in stool until he died 15 days later having developed acute encephalopathy.

Case 4 was symptom-free and had no spores in stool during the following six weeks. Thereafter clinical and parasitological relapse occurred, and a new cycle with furazolidone was administered. The patient showed remission of symptoms within two weeks of starting treatment, and transient clearance of spore shedding in stool after therapy. Subsequently, although intermittent shedding of rare to very rare spores was documented in stool, he had no

by sequential washing in deionised water followed by modified sugar flotation and high speed centrifugation. Specimens were then transferred to microfuge tubes, washed in 0.1 M phosphate buffer (pH 7.4) and post-fixed in 2% osmium tetroxide for two hours, resuspended in fixative, and centrifuged at 9000 × g for five minutes in a microcentrifuge. After being washed and dehydrated in graded ethanol series, the pellets were embedded in resin, sectioned, stained with uranyl acetate and Reynold’s lead citrate, and examined by TEM.

All patients underwent a baseline laboratory evaluation that included full blood cell count, urine analysis, electrolytes, and liver function tests.
diarrhoea over the following four months until he died from systemic Mycobacterium avium infection.

Case 5 was asymptomatic, even though very rare spores were intermittently documented in stool, until he died 11 weeks later having developed systemic cryptococcosis.

Case 6 had long lasting clinical remission and body weight increase. Although rare to very rare spores were occasionally detected in stool, this patient was free from symptoms four months after completion of treatment and had gained 3 kg in weight.

PARASITE MORPHOLOGY IN STOOL

Light microscopy

In all patients alterations in faecal spores were detected by Weber’s method after treatment. In these cases the pinkish-red belt-like stripe as originally described by Weber et al was replaced by a marked red stained clot (fig 1); however, spore shape and size was normal. The number of dysmorphous spores was variable, ranging from 1 to 50 in each microscopic field (mean 10). Changed spores were intermittently excreted, and coexisted with normal spores with a mean ratio of 5:1. Alterations in faecal spores were not demonstrated by Van Gool’s method.

Transmission electron microscopy

TEM study of stool samples collected after therapy demonstrated E. bieneusi spores with normal polar tubes but a wavy wall outline.

PARASITE MORPHOLOGY IN BIOPSY SPECIMENS

Only normal stages of E. bieneusi were observed in all studied ultramicroscopic fields from the biopsies taken before treatment (fig 2). After treatment parasite abnormalities at all stages of the life cycle were documented in biopsies from the three studied patients and appeared most pronounced in parasites undergoing their sporogony phases. In these cases disarrangement of nuclei chromatin was constantly present (figs 3–5), disruption of nuclear membrane, irregularity of nuclear outline, and apparent separation of nuclear membrane from the nucleoplasm were also frequently seen (figs 4 and 5).

Moreover, about half of sporogonial plasmodia seen in the examined fields showed electron dense discs (EDDS) that failed to develop into polar tubes and appeared disorganised, deformed, disrupted, and pale (figs 3–5). Sporoblasts showed disarrangement of nuclear chromatin similar to that observed in sporogonial plasmodia. Most spores had an irregular outline with diastasis between the spore and the enterocyte cytoplasm suggesting shrinking; however, the polar tubes were unchanged (fig 6).

No alterations in host cell structures were observed in biopsy specimens taken before and after treatment.

Discussion

Furazolidone treatment in six patients with E. bieneusi intestinal infection led to symptomatic relief and decrease (or transient absence) of spore shedding in stool. Subsequently, two patients showed clinical and parasitological relapse during the second and third month following discontinuation of therapy; however, clinical and parasitological remission was achieved by a new course of treatment.

Biopsy specimens from the three patients who underwent post-treatment endoscopy showed ultrastructural changes in E. bieneusi at all stages of the life cycle, although these were more pronounced for sporogonial plasmodia whose nuclei constantly showed alterations. Many sporogonial plasmodia showed severe changes in EDDS, and most spores showed a distorsion in their outline that suggests shrinking.

Although abnormalities of nuclei have been described in E. bieneusi after albendazole treatment, to our knowledge marked changes in EDDS have not been reported previously. EDDS are essential to the harmful potential of microsporidia, being precursors of polar tubes. Therefore, the impaired development of EDDS found in sporogonial plasmodia probably indicates a proportionally impaired offending activity of E. bieneusi. Distortion in spore outline observed in biopsy samples is difficult to explain; however, we can exclude that it was an artefact, as cell organelles surrounding the spores were normal.

The alterations in developmental stages of E. bieneusi seen in biopsy specimens by TEM can justify the presence of dysmorphous spores in stool in all patients. To our knowledge, these changes in faecal spores observed by Weber’s method after furazolidone treatment have not been reported previously after any other treatment for E. bieneusi and were not seen in our patients before treatment. Alterations in faecal spores were not demonstrated by Van Gool’s method, as the fluorochrome employed in this method does not penetrate spores, but only binds to chitin, a component of the microsporidian spore wall.

The electron microscopic alterations observed on biopsies taken after treatment suggest that furazolidone has a direct activity on E. bieneusi, likely by inhibiting parasite mul-
tiplication. This hypothesis is supported by the observed decrease of parasite load in stool and by the subsequent symptomatic relief. Furazolidone, however, was not able to eradicate *E. bieneusi* infection as, in spite of treatment, some parasites accomplished normal development, giving rise to normal spores. In spite of its small size, this study seems to demonstrate the efficacy of a new drug for the treatment of *E. bieneusi* intestinal microsporidiosis. The observed symptomatic relief due to furazolidone strictly correlated with the morphological changes of the life cycle of the parasite.

Enterocytozoon bieneusi in AIDS: symptomatic relief and parasite changes after furazolidone.

D Dionisio, L I Manneschi, S Di Lollo, A Orsi, G Sterratino, M Meli, M Gabbrielli, A Tani, A Papucci and F Leoncini

doi: 10.1136/jcp.50.6.472

Updated information and services can be found at:
[http://jcp.bmj.com/content/50/6/472](http://jcp.bmj.com/content/50/6/472)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)